MDR1 gene polymorphisms may be associated with Behçet's disease and its colchicum treatment response

Gene

Volumn 505, Issue 2, 2012, Pages 333-339

  Rustemoglu, Aydin ^a   Gül, Ülker ^b   Gümüş Akay, Güvem ^c   Gönül, Müzeyyen ^b   Yiǧit, Serbülent ^a   Bozkurt, Nihan ^a   Karadaǧ, Aynur ^c   Pişkin, Emine ^b   Sunguroǧlu, Asuman ^c   Kadikiran, Ahmet ^c  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

ABCB1; Beh et's disease; Polymorphism; SNP; Turkey

Indexed keywords

COLCHICINE; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ALLELE; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE DURATION; ERYTHEMA NODOSUM; FEMALE; GENE LOCUS; GENETIC PREDISPOSITION; GENITAL ULCER; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUSTULE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; BEHCET SYNDROME; COLCHICINE; COLCHICUM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUBULIN MODULATORS;

COLCHICUM;

EID: 84864137130     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.05.040     Document Type: Article

References (37)

1. Arber N., Klein T., Meiner Z., Pras E., Weinberger A. Close association of HLA-B51 and B52 in Israeli patients with Behçet's syndrome. Ann. Rheum. Dis. 1991, 50(6):351-353.
2. Behcet H. Uber rezidivivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol. Wochenschr. 1937, 105:1152-1157.
3. Ben-Chetrit E., Levy M. Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy pf colchicine in familial Mediterranean fever and other inflammatory diseases?. Med. Hypotheses 1998, 51:377-380.
4. Borlu M., Ukşal Ü., Ferahbaş A., Evereklioǧlu C. Clinical features of Behçet's disease in children. Int. J. Dermatol. 2006, 45:713-716.
5. Chen J., Chen L., Mao N., Liu Y. Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population. Rheumatol. Int. 2011, (Sep 24 (Epub ahead of print)). 10.1007/s00296-011-2088-3.
6. Dalghous A.M., Freysdottir J., Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand. J. Rheumatol. 2006, 35(6):472-475.
7. Diaz-Borjon A., Richaud-Patin Y., Alvarado de la Barrera C., Jakez-Ocampo J., Ruiz-Arguelles A., Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 2000, 67:40-48.
8. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. 2001, 60:996-1002.
9. Drozdzik M., et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 2006, 62(11):933-937.
10. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv. Ophthalmol. 2005, 50(4):297-350.
11. Gréen H., Söderkvist P., Rosenberg P., Horvath G., Peterson C. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 2006, 12(3 Pt. 1):854-859.
12. Gül A. Behçet's disease as an autoinflammatory disorder. Curr. Drug Targets Inflamm. Allergy 2005, 4:81-83.
13. Gupta S., Kim C.H., Tsuruo T., Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J. Clin. Immunol. 1992, 12:451-458.
14. Hamurcu Z., Dönmez-Altuntaş H., Borlu M., Demirtaş H., Asçioslu Ö. Micronucleus frequency in the oral mucosa and lymphocytes of patients with Behçet's disease. Exp. Dermatol. 2005, 30:565-569.
15. Hirohata S., Kikuchi H. Behçet's disease. Arthritis Res. Ther. 2003, 5:139-146.
16. Hornung V., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168(9):4531-4537.
17. http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?chooseRs=coding&locusId=5243&mrna.
18. Illmer T., et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002, 62:4955-4962.
19. Evaluation of diagnostic ("classification") criteria in Behçet's disease: toward internationally agreed criteria. Behçet's Disease: Basic and Clinical Aspects 1991, 11-39. International Study Group for Behçet's Disease Contributors, Marcel Dekker, New York. O.'. Duffy, B. Kökmen (Eds.).
20. Kafka A., et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 2003, 22(5):1117-1121.
21. Kaneko F., et al. Behçet's disease (Adamantiades-Behçet's disease). Clin. Dev. Immunol. 2011, 2011:1-7.
22. Kim D.H., et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int. J. Cancer 2006, 118:2195-2201.
23. Kimchi-Sarfaty C., et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 2007, 8:29-39.
24. Kroetz D.L., et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481-494.
25. Llorente L., et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000, 67:30-39.
26. Ohno S., Onguchi M., Hirose S. Close association of HLA-Bw51 with Behçet's disease. Arch. Ophthalmol. 1982, 100(9):1455-1458.
27. Ozdogu H., Boga C., Yilmaz Z., Sahin F.I., Bal N. Long-term colchicine therapy in a patient with Behçet's disease and acute promyelocytic leukemia. Rheumatol. Int. 2007, 27:763-765.
28. Rabinovich E., Shinar Y., Leiba M., Ehrenfeld M., Langevitz P., Livneh A. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand. J. Rheumatol. 2007, 36(1):48-52.
29. Rustemoglu A., Gumus-Akay G., Yigit S., Tasliyurt T. Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial Mediterranean fever. Genet. Mol. Res. 2011, 10(4):3411-3420.
30. Sai K., et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003, 13:741-757.
31. Sakaeda T. MDR1 genotype-related pharmacogenetics: fact or fiction?. Drug Metab. Pharmacokinet. 2005, 20:391-414.
32. Saricaoglu H., et al. Investigation of ABCB1 gene polymorphism with colchicine response in Behçet's disease. Genet. Mol. Res. 2011, 10(1):1-6.
33. Schwab M., Eichelbaum M., Fromm M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 2003, 43:285-307.
34. Suzuki Y., Hoshi K., Matsuda T., Mizushima Y. Increased peripheral blood gamma delta+ T cells and natural killer cells in Behçet's disease. J. Rheumatol. 1992, 19(4):588-592.
35. Tang K., Ngoi S.M., Chua J.M., Lee E.J., Chong S.S., Lee C.G. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002, 12:437-450.
36. Tufan A., et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J. Rheumatol. 2007, 34:1540-1544.
37. Yanagihori H., Oyama N., Nakamura K., Mizuki N., Oguma K., Kaneko F. Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: an involvement of Th1 immunoreactivity against Streptococcus sanguinis antigen. J. Invest. Dermatol. 2006, 126(7):1534-1540.